These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38577865)

  • 1. Polymers and their engineered analogues for ocular drug delivery: Enhancing therapeutic precision.
    Biswas A; Kumar S; Choudhury AD; Bisen AC; Sanap SN; Agrawal S; Mishra A; Verma SK; Kumar M; Bhatta RS
    Biopolymers; 2024 Jul; 115(4):e23578. PubMed ID: 38577865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.
    Mandal A; Bisht R; Rupenthal ID; Mitra AK
    J Control Release; 2017 Feb; 248():96-116. PubMed ID: 28087407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid in ocular drug delivery.
    Zhang X; Wei D; Xu Y; Zhu Q
    Carbohydr Polym; 2021 Jul; 264():118006. PubMed ID: 33910737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on revolutionizing ophthalmic therapy: Unveiling the potential of chitosan, hyaluronic acid, cellulose, cyclodextrin, and poloxamer in eye disease treatments.
    Wang TJ; Rethi L; Ku MY; Nguyen HT; Chuang AE
    Int J Biol Macromol; 2024 Jul; 273(Pt 2):132700. PubMed ID: 38879998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymer-based carriers for ophthalmic drug delivery.
    Imperiale JC; Acosta GB; Sosnik A
    J Control Release; 2018 Sep; 285():106-141. PubMed ID: 29964135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.
    Tsung TH; Tsai YC; Lee HP; Chen YH; Lu DW
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
    Durgun ME; Güngör S; Özsoy Y
    J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell penetrating peptides in ocular drug delivery: State of the art.
    Pescina S; Ostacolo C; Gomez-Monterrey IM; Sala M; Bertamino A; Sonvico F; Padula C; Santi P; Bianchera A; Nicoli S
    J Control Release; 2018 Aug; 284():84-102. PubMed ID: 29913221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
    Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS
    AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
    Wang R; Gao Y; Liu A; Zhai G
    J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of therapeutics for deep-seated ocular conditions - status quo.
    Nguyen H; Eng S; Ngo T; Dass CR
    J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Mini-review on New Developments in Nanocarriers and Polymers for Ophthalmic Drug Delivery Strategies.
    Sharma Y; Patel P; Kurmi BD
    Curr Drug Deliv; 2024; 21(4):488-508. PubMed ID: 37143264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application.
    Tsai CH; Wang PY; Lin IC; Huang H; Liu GS; Tseng CL
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30235809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics.
    Datta D; Priyanka Bandi S; Colaco V; Dhas N; Siva Reddy DV; Vora LK
    Int J Pharm; 2024 Jun; 658():124192. PubMed ID: 38703931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular drug delivery-eye on innovation.
    Rupenthal ID; O'Rourke M
    Drug Deliv Transl Res; 2016 Dec; 6(6):631-633. PubMed ID: 27766597
    [No Abstract]   [Full Text] [Related]  

  • 17. Hyaluronic acid modified MPEG-b-PAE block copolymer aqueous micelles for efficient ophthalmic drug delivery of hydrophobic genistein.
    Li C; Chen R; Xu M; Qiao J; Yan L; Guo XD
    Drug Deliv; 2018 Nov; 25(1):1258-1265. PubMed ID: 29847210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of ocular drug delivery systems using molecularly imprinted soft contact lenses.
    Tashakori-Sabzevar F; Mohajeri SA
    Drug Dev Ind Pharm; 2015 May; 41(5):703-13. PubMed ID: 25113431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
    Fangueiro JF; Veiga F; Silva AM; Souto EB
    Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.